TAKHZYRO 300 mg, Injektionslösung im Fertigpen

7680701500011 CH-70150 Injektionslösung im Fertigpen
TAKHZYRO 300 mg, Injektionslösung im Fertigpen
TAKHZYRO 300 mg, Injektionslösung im Fertigpen
TAKHZYRO 300 mg, Injektionslösung im Fertigpen
1 / 3
google

Article details

Package size
1
Selling units
unbekannt
Measure
Fertigpen zu 2 ml
Galenic form
Injektionslösung im Fertigpen
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
10/07/2026
Patient information leaflet
Français
10/07/2026
Patient information leaflet
Italien
10/07/2026

Detailed composition

Substance Quantity Type Category
lanadelumabum
300.0 MG Substance Wirkstoff (Principe actif)
dinatrii phosphas dihydricus
- Substance HNIDK
acidum citricum monohydricum
- Substance HNIDK
histidinum
- Substance HNIDK
natrii chloridum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
6.91 MG Substance HBESI

Reimbursement information

Public price
CHF 9964.85
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/06/2026

Authorization holder

Takeda Pharma AG

8152 Opfikon

Authorization information

Swissmedic authorization number
70150
Drug name
TAKHZYRO, Injektionslösung im Fertigpen
Galenic form
INLFP
ATC Code
B06AC05
Authorization status
Z
Dispensing category
B
First authorization
19/02/2026
Authorization expiration date
18/02/2031
IT Number
02.99.0.
Domain
Human medicine
Field of application
Langzeitprophylaxe von Attacken des hereditären Angioödems

Package details

Description (FR)
TAKHZYRO sol inj 300 mg/2ml stylo prérempli 1 pce
Description (DE)
TAKHZYRO Inj Lös 300 mg/2ml Fertigpen 1 Stk
Market launch
19/02/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data